Neuroblastoma Treatment Market by Therapy (Chemotherapy, Immunotherapy and Radiotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores): Global Industry Perspective, Comprehensive Analysis and Forecast, 2020 – 2028

Published Date: 13-May-2021 Category: Medical Device Report Format : PDF Pages: 150 Report Code: ZMR-18 Status : Published

The neuroblastoma treatment market accounted for USD 2904 Million in 2020 and is expected to reach USD 3854 Million by 2028, growing at a CAGR of 3.6% from 2021 to 2028.

Description

Market Overview

The neuroblastoma treatment market accounted for USD 2904 Million in 2020 and is expected to reach USD 3854 Million by 2028, growing at a CAGR of 3.6% from 2021 to 2028.

Neuroblastoma is amongst the foremost common cancers affecting infants under the age of 1to 5. The condition accounts for nearly 6% of all cancers in children, especially in developed countries like the U.S. Also, an estimated 800 new cases of neuroblastoma are reported annually within the U.S. The increasing burden of the condition is anticipated to push demand for treating the disease. The cancer is caused because of embryonal malignancy of sympathetic systema nervosum which arises from the neuroblasts. The cancer develops within the nerve tissues of adrenal, chest, or medulla spinalis. Neuroblastoma is listed as a “rare disease” within the U.S. by the National Institute of Health (NIH), and Orphaned in Europe. The cancer is most prevalent in infants below 5 years aged, with peak age bracket of two to three years.

COVID-19 Impact Analysis

With the continued COVID-19 pandemic healthcare workers are exercising caution and stepping up treatment to guard cancer afflicted children from infection. Though the COVID-19 pandemic appears to largely spare children, practitioners are warning researchers to review the potential impacts the virus can wear paediatric patients to seek out the acceptable response just in case of an infection. It is a standard understanding amongst medical professionals that the danger of COVID-19 infection can increase in immunocompromised children with cancer, leading to increased morbidity and mortality. Most childhood cancers have an aggressive course and need immediate treatment, often involving prolonged durations of intensive multi-agent chemotherapy. Postponement of therapy is therefore not an option.

Realizing the potential risks faced by paediatric Neuroblastoma patients, key players within the market are leveraging their research in preventing potential infection of those patients by the novel COVID-19 virus.

Growth Factors

R&D activities of Neuroblastoma Treatment Market is one of the growth factors. The global market will benefit from research and development for the treatment of relapsed refractory neuroblastoma. Improved understanding of the aetiology of neuroblastoma has led to the discovery of new tumour targets and novel therapeutic methods. Molecular and genetic tumour profiling are being used in many ongoing clinical trials to target tumour-specific aberrations. As a result, increased R&D would drive demand growth over the forecast period.

The second growth factor is advanced technologies market growth. High technical advances and the availability of orphan drugs are assisting in the approval process, which is fostering the development of the industry.

Report Scope:

Therapy Segment Analysis

Chemotherapy (chemo) uses anti-cancer drugs, which are generally given into a vein. The drugs enter the bloodstream and travel throughout the body to succeed in and obliterate cancer cells. This makes chemo useful for treating neuroblastoma that has spread to the lymph nodes, bone marrow, liver, lungs, or other organs.

Whether an infant with neuroblastoma will get chemotherapy differs on their risk group. Some children with neuroblastoma are cured with chemo either before surgery (neoadjuvant chemotherapy) or after surgery (adjuvant chemotherapy).

Immunotherapy is that the use of medicines to assist a patient’s own system recognize and obliterate cancer cells more effectively. Immune helps your system fight cancer. Immunotherapy drugs are approved to treat many sorts of cancer. However, immunotherapy is not yet as widely used as surgery, chemotherapy, or radiotherapy.

Distribution Channel Segment Analysis

Hospital Pharmacies channel dominated the market and is predicted to sustain its leadership position in terms of market share during the forecast period. This is often acknowledgments to high preference for hospital pharmacies for purchasing drugs prescribed for cancer treatment.

Drug Stores of Neuroblastoma treatment market provides high cost of medication due to the long duration of procedures and demand. Drugs for the treatment of neuroblastoma, especially immunotherapy drugs, are very costly. As a result, the production costs of these drugs rise, as do their prices.

Regional Analysis Preview

As per analysis, North America would account for a dominant share with CAGR of 3.4% within the market over the forecast period and variety of things would push it thereto position, high incidence of neuroblastoma is being reported in the North American region. This is contributing tremendously to development, which is projected for the area. The healthcare system in this city is solid, which is reflected in the positive statistics. Furthermore, in the regional sector, a better reimbursement system and increasing knowledge are major growth propellers.

In terms of revenue share, Europe is second due to the existence of favourable government programmes for improving respiratory care, such as the European Committee for Hyperbaric Medicine (ECHM), which is active in raising awareness about the procedure.

The Neuroblastoma Treatment Market is segmented as follows:

By Therapy

  • Chemotherapy
  • Immunotherapy
  • Radiotherapy

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter No. 1: Introduction
    • 1.1. Report Description
      • 1.1.1. Purpose of the Report
      • 1.1.2. USP & Key Offerings
    • 1.2. Key Benefits for Stakehulders
    • 1.3. Target Audience
    • 1.4. Report Scope
  • Chapter No. 2: Executive Summary
    • 2.1. Key Findings
      • 2.1.1. Top Investment Pockets
        • 2.1.1.1. Market Attractiveness Analysis, By Component
        • 2.1.1.2. Market Attractiveness Analysis, By Application
        • 2.1.1.3. Market Attractiveness Analysis, By End Use Industry
        • 2.1.1.4. Market Attractiveness Analysis, By Region
    • 2.2. Market Snapshot
    • 2.3. Global Neuroblastoma Treatment Market, 2016 – 2028 (USD Million)
    • 2.4. Insights from Primary Respondents
  • Chapter No. 3: COVID 19 Impact Analysis
    • 3.1. Impact Assessment of COVID-19 Pandemic, By Region
      • 3.1.1. North America
      • 3.1.2. Europe
      • 3.1.3. Asia Pacific
      • 3.1.4. Latin America
      • 3.1.5. Middle East & Africa
    • 3.2. Quarterly Market Revenue and Forecast by Region 2020 & 2021
    • 3.3. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Million)
    • 3.4. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Million)
    • 3.5. Key Strategies Undertaken by Companies to Tackle COVID-19
      • 3.5.1. Company Quarterly Revenue Analysis, 2019 & 2020
    • 3.6. Short Term Dynamics
    • 3.7. Long Term Dynamics
  • Chapter No. 4: Neuroblastoma Treatment Market – Component Segment Analysis
    • 4.1. Overview
      • 4.1.1. Market Revenue Share, By Component, 2020 & 2028
    • 4.2. Software
      • 4.2.1. Market Size and Forecast, By Region (USD Million)
      • 4.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.3. Service
      • 4.3.1. Market Size and Forecast, By Region, 2016 – 2028 (USD Million)
      • 4.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.3.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 5: Neuroblastoma Treatment Market – Application Segment Analysis
    • 5.1. Overview
      • 5.1.1. Market Revenue Share, By Application, 2020 & 2028
    • 5.2. Marketing
      • 5.2.1. Market Size and Forecast, By Region, 2016 – 2028 (USD Million)
      • 5.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.3. Operations
      • 5.3.1. Market Size and Forecast, By Region, 2016 – 2028 (USD Million)
      • 5.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.4. Finance
      • 5.4.1. Market Size and Forecast, By Region, 2016 – 2028 (USD Million)
      • 5.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.4.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.5. Human Resource
      • 5.5.1. Market Size and Forecast, By Region, 2016 – 2028 (USD Million)
      • 5.5.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.5.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.6. Others
      • 5.6.1. Market Size and Forecast, By Region, 2016 – 2028 (USD Million)
      • 5.6.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.6.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 6: Neuroblastoma Treatment Market – End Use Industry Segment Analysis
    • 6.1. Overview
      • 6.1.1. Market Revenue Share, By End Use Industry, 2020 & 2028
    • 6.2. Manufacturing
      • 6.2.1. Market Size and Forecast, By Region, 2016 – 2028 (USD Million)
      • 6.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 6.3. Hospitality
      • 6.3.1. Market Size and Forecast, By Region, 2016 – 2028 (USD Million)
      • 6.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 6.4. BFSI
      • 6.4.1. Market Size and Forecast, By Region, 2016 – 2028 (USD Million)
      • 6.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.4.3. Key Market Trends, Growth Factors, & Opportunities
    • 6.5. Retail
      • 6.5.1. Market Size and Forecast, By Region, 2016 – 2028 (USD Million)
      • 6.5.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.5.3. Key Market Trends, Growth Factors, & Opportunities
    • 6.6. IT & Telecom
      • 6.6.1. Market Size and Forecast, By Region, 2016 – 2028 (USD Million)
      • 6.6.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.6.3. Key Market Trends, Growth Factors, & Opportunities
    • 6.7. Others
      • 6.7.1. Market Size and Forecast, By Region, 2016 – 2028 (USD Million)
      • 6.7.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.7.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 7: Neuroblastoma Treatment Market – Regional Analysis
    • 7.1. Overview
      • 7.1.1. Global Market Revenue Share, By Region, 2020 & 2028
      • 7.1.2. Global Market Revenue, By Region, 2016 – 2028 (USD Million)
    • 7.2. North America
      • 7.2.1. North America Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 7.2.2. North America Market Revenue, By Component, 2016 – 2028
      • 7.2.3. North America Market Revenue, By Application, 2016 – 2028
      • 7.2.4. North America Market Revenue, By End Use Industry, 2016 – 2028
      • 7.2.5. U.S.
        • 7.2.5.1. U.S. Market Revenue, By Component, 2016 – 2028
        • 7.2.5.2. U.S. Market Revenue, By Application, 2016 – 2028
        • 7.2.5.3. U.S. Market Revenue, By End Use Industry, 2016 – 2028
      • 7.2.6. Canada
        • 7.2.6.1. Canada Market Revenue, By Component, 2016 – 2028
        • 7.2.6.2. Canada Market Revenue, By Application, 2016 – 2028
        • 7.2.6.3. Canada Market Revenue, By End Use Industry, 2016 – 2028
      • 7.2.7. Mexico
        • 7.2.7.1. Mexico Market Revenue, By Component, 2016 – 2028
        • 7.2.7.2. Mexico Market Revenue, By Application, 2016 – 2028
        • 7.2.7.3. Mexico Market Revenue, By End Use Industry, 2016 – 2028
    • 7.3. Europe
      • 7.3.1. Europe Market Revenue, 2016 - 2028 (USD Million)
      • 7.3.2. Europe Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 7.3.3. Europe Market Revenue, By Component, 2016 – 2028
      • 7.3.4. Europe Market Revenue, By Application, 2016 – 2028
      • 7.3.5. Europe Market Revenue, By End Use Industry, 2016 – 2028
      • 7.3.6. Germany
        • 7.3.6.1. Germany Market Revenue, By Component, 2016 – 2028
        • 7.3.6.2. Germany Market Revenue, By Application, 2016 – 2028
        • 7.3.6.3. Germany Market Revenue, By End Use Industry, 2016 – 2028
      • 7.3.7. France
        • 7.3.7.1. France Market Revenue, By Component, 2016 – 2028
        • 7.3.7.2. France Market Revenue, By Application, 2016 – 2028
        • 7.3.7.3. France Market Revenue, By End Use Industry, 2016 – 2028
      • 7.3.8. U.K.
        • 7.3.8.1. U.K. Market Revenue, By Component, 2016 – 2028
        • 7.3.8.2. U.K. Market Revenue, By Application, 2016 – 2028
        • 7.3.8.3. U.K. Market Revenue, By End Use Industry, 2016 – 2028
      • 7.3.9. Italy
        • 7.3.9.1. Italy Market Revenue, By Component, 2016 – 2028
        • 7.3.9.2. Italy Market Revenue, By Application, 2016 – 2028
        • 7.3.9.3. Italy Market Revenue, By End Use Industry, 2016 – 2028
      • 7.3.10. Spain
        • 7.3.10.1. Spain Market Revenue, By Component, 2016 – 2028
        • 7.3.10.2. Spain Market Revenue, By Application, 2016 – 2028
        • 7.3.10.3. Spain Market Revenue, By End Use Industry, 2016 – 2028
      • 7.3.11. Rest of Europe
        • 7.3.11.1. Rest of Europe Market Revenue, By Component, 2016 – 2028
        • 7.3.11.2. Rest of Europe Market Revenue, By Application, 2016 – 2028
        • 7.3.11.3. Rest of Europe Market Revenue, By End Use Industry, 2016 – 2028
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific Market Revenue, 2016 - 2028 (USD Million)
      • 7.4.2. Asia Pacific Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 7.4.3. Asia Pacific Market Revenue, By Component, 2016 – 2028
      • 7.4.4. Asia Pacific Market Revenue, By Application, 2016 – 2028
      • 7.4.5. Asia Pacific Market Revenue, By End Use Industry, 2016 – 2028
      • 7.4.6. China
        • 7.4.6.1. China Market Revenue, By Component, 2016 – 2028
        • 7.4.6.2. China Market Revenue, By Application, 2016 – 2028
        • 7.4.6.3. China Market Revenue, By End Use Industry, 2016 – 2028
      • 7.4.7. Japan
        • 7.4.7.1. Japan Market Revenue, By Component, 2016 – 2028
        • 7.4.7.2. Japan Market Revenue, By Application, 2016 – 2028
        • 7.4.7.3. Japan Market Revenue, By End Use Industry, 2016 – 2028
      • 7.4.8. India
        • 7.4.8.1. India Market Revenue, By Component, 2016 – 2028
        • 7.4.8.2. India Market Revenue, By Application, 2016 – 2028
        • 7.4.8.3. India Market Revenue, By End Use Industry, 2016 – 2028
      • 7.4.9. South Korea
        • 7.4.9.1. South Korea Market Revenue, By Component, 2016 – 2028
        • 7.4.9.2. South Korea Market Revenue, By Application, 2016 – 2028
        • 7.4.9.3. South Korea Market Revenue, By End Use Industry, 2016 – 2028
      • 7.4.10. South-East Asia
        • 7.4.10.1. South-East Asia Market Revenue, By Component, 2016 – 2028
        • 7.4.10.2. South-East Asia Market Revenue, By Application, 2016 – 2028
        • 7.4.10.3. South-East Asia Market Revenue, By End Use Industry, 2016 – 2028
      • 7.4.11. Rest of Asia Pacific
        • 7.4.11.1. Rest of Asia Pacific Market Revenue, By Component, 2016 – 2028
        • 7.4.11.2. Rest of Asia Pacific Market Revenue, By Application, 2016 – 2028
        • 7.4.11.3. Rest of Asia Pacific Market Revenue, By End Use Industry, 2016 – 2028
    • 7.5. Latin America
      • 7.5.1. Latin America Market Revenue, 2016 - 2028 (USD Million)
      • 7.5.2. Latin America Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 7.5.3. Latin America Market Revenue, By Component, 2016 – 2028
      • 7.5.4. Latin America Market Revenue, By Application, 2016 – 2028
      • 7.5.5. Latin America Market Revenue, By End Use Industry, 2016 – 2028
      • 7.5.6. Brazil
        • 7.5.6.1. Brazil Market Revenue, By Component, 2016 – 2028
        • 7.5.6.2. Brazil Market Revenue, By Application, 2016 – 2028
        • 7.5.6.3. Brazil Market Revenue, By End Use Industry, 2016 – 2028
      • 7.5.7. Argentina
        • 7.5.7.1. Argentina Market Revenue, By Component, 2016 – 2028
        • 7.5.7.2. Argentina Market Revenue, By Application, 2016 – 2028
        • 7.5.7.3. Argentina Market Revenue, By End Use Industry, 2016 – 2028
      • 7.5.8. Rest of Latin America
        • 7.5.8.1. Rest of Latin America Market Revenue, By Component, 2016 – 2028
        • 7.5.8.2. Rest of Latin America Market Revenue, By Application, 2016 – 2028
        • 7.5.8.3. Rest of Latin America Market Revenue, By End Use Industry, 2016 – 2028
    • 7.6. Middle East & Africa
      • 7.6.1. Middle East & Africa Market Revenue, 2016 - 2028 (USD Million)
      • 7.6.2. Middle East & Africa Market Revenue, By Component, 2016 – 2028
      • 7.6.3. Middle East & Africa Market Revenue, By Application, 2016 – 2028
      • 7.6.4. Middle East & Africa Market Revenue, By End Use Industry, 2016 – 2028
  • Chapter No. 8 Neuroblastoma Treatment Market – Industry Analysis
    • 8.1. Introduction
    • 8.2. Market Drivers
      • 8.2.1. Driving Factor 1 Analysis
      • 8.2.2. Driving Factor 2 Analysis
    • 8.3. Market Restraints
      • 8.3.1. Restraining Factor Analysis
    • 8.4. Market Opportunities
      • 8.4.1. Market Opportunity Analysis
    • 8.5. Porter’s Five Forces Analysis
    • 8.6. PEST Analysis
    • 8.7. Regulatory Landscape
    • 8.8. Technulogy Landscape
    • 8.9. Regional Market Trends
      • 8.9.1. North America
      • 8.9.2. Europe
      • 8.9.3. Asia Pacific
      • 8.9.4. Latin America
      • 8.9.5. Middle East & Africa
    • 8.10. Pricing Analysis
    • 8.11. Value Chain Analysis
    • 8.12. Downstream Buyers
    • 8.13. Distributors/Traders List
  • Chapter No. 9: Competitive Landscape
    • 9.1. Company Market Share Analysis – 2019
      • 9.1.1. Global Neuroblastoma Treatment Market: Company Market Share, 2019
      • 9.1.2. Global Neuroblastoma Treatment Market, Company Market Revenue, 2016 – 2019 (USD Million)
      • 9.1.3. Global Neuroblastoma Treatment Market, Company Y-o-Y Growth, 2017 – 2019 (%)
      • 9.1.4. Global Neuroblastoma Treatment Market: Radar Determinant Chart, 2019
    • 9.2. Strategic Developments
      • 9.2.1. Acquisitions & Mergers
      • 9.2.2. New Product Launch
      • 9.2.3. Regional Expansion
    • 9.3. Company Strategic Developments – Heat Map Analysis
  • Chapter No. 10: Company Profiles
    • 10.1. Oracle Corporation
      • 10.1.1. Company Overview
      • 10.1.2. Key Executives
      • 10.1.3. Product Portfulio
      • 10.1.4. Financial Overview
      • 10.1.5. Operating Business Segments
      • 10.1.6. Business Performance
      • 10.1.7. Recent Developments
    • 10.2. SAP SE
    • 10.3. SAS Institute, Inc.
    • 10.4. Capgemini
    • 10.5. CA Technulogies
    • 10.6. Workiva
    • 10.7. IBM Corporation
    • 10.8. Emtec
    • 10.9. The Hackett Group
    • 10.10. MicroStrategy, Inc.
  • Chapter No. 11: Marketing Strategy Analysis
    • 11.1. Marketing Channel
    • 11.2. Direct Marketing
    • 11.3. Indirect Marketing
    • 11.4. Marketing Channel Development Trends
    • 11.5. Economic/Pulitical Environmental Change
  • Chapter No. 12: Research Methodulogy
    • 12.1. Research Methodulogy
    • 12.2. Phase I - Secondary Research
    • 12.3. Phase II - Data Modelling
      • 12.3.1. Company Share Analysis Model
      • 12.3.2. Revenue Based Modelling
    • 12.4. Phase III - Primary Research
    • 12.5. Research Limitations
      • 12.5.1. Assumptions

Methodology


Frequently Asked Questions

The neuroblastoma treatment market was valued at USD 2904 Million in 2020.

The neuroblastoma treatment market is expected to reach USD 3854 Million by 2028, growing at a CAGR of 3.6 % from 2021 to 2028.

Factors driving the worldwide neuroblastoma treatment market is that the growth of Biotechnology companies' R&D initiatives focused on neuroblastoma studies are expected to drive demand and High technical advances and the availability of orphan drugs are assisting in the approval process, which is fostering the development of the industry. Hence, these are few key factors which are driving market growth.

Because of its high acceptance rate of technologically advanced goods, North America is expected to maintain its dominance. In the global paediatric neuroblastoma treatment market, Europe is expected to rise at the fastest pace. Neuroblastoma occurrence is on the rise, and medication approvals are on the rise, according to experts.

Companies such as United Therapeutics Corporation, APEIRON Biologics AG, Baxter International, APAC Biotech, Sun Pharmaceutical Industries, Inc., Pfizer Inc., MacroGenics Inc.
}
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com